Author
Listed:
- Marek Mazurek
(Department of Surgical Oncology, Voivodship Hospital in Siedlce, 08-110 Siedlce, Poland)
- Małgorzata Szlendak
(Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland
Department of Oncology, Medical University of Warsaw, 02-097 Warsaw, Poland)
- Alicja Forma
(Department of Forensic Medicine, Medical University of Lublin, 20-090 Lublin, Poland)
- Jacek Baj
(Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland)
- Ryszard Maciejewski
(Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland)
- Giandomenico Roviello
(Department of Health Sciences, University of Florence, 50139 Florence, Italy)
- Luigi Marano
(Department of General Surgery and Surgical Oncology, University of Siena, 53100 Siena, Italy)
- Franco Roviello
(Department of General Surgery and Surgical Oncology, University of Siena, 53100 Siena, Italy)
- Karol Polom
(Department of Surgical Oncology, Medical University of Gdansk, 80-070 Gdansk, Poland
These authors contributed equally to this article.)
- Robert Sitarz
(Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland
Department of Surgical Oncology, St. John’s Cancer Center, 20-090 Lublin, Poland
These authors contributed equally to this article.)
Abstract
Gastric cancer (GC) patients with peritoneal metastasis tend to achieve poor clinical outcomes. Until recently, the treatment options were limited mainly to either palliative chemotherapy or radiation therapy in exceptional cases. Currently, these patients benefit from multimodal treatment, such as cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Despite good overall results, this treatment modality is still widely debated. The following study is designed to assess the papers about the possible application and utility of HIPEC in GC. A search in the PubMed, Web of Science, and Scopus databases was performed to assess the papers devoted to the role of HIPEC in GC treatment; a literature search was performed until March 21st; and, finally, 50 studies with a total number of 3946 patients were analyzed. According to the most recent data, it seems to be reasonable to limit the duration of HIPEC to the shortest effective time. Moreover, the drugs used in HIPEC need to have equal concentrations and the same solvent. Perioperative chemotherapy needs to be reported in detail and, furthermore, the term “morbidity” should be defined more clearly by the authors.
Suggested Citation
Marek Mazurek & Małgorzata Szlendak & Alicja Forma & Jacek Baj & Ryszard Maciejewski & Giandomenico Roviello & Luigi Marano & Franco Roviello & Karol Polom & Robert Sitarz, 2022.
"Hyperthermic Intraperitoneal Chemotherapy in the Management of Gastric Cancer: A Narrative Review,"
IJERPH, MDPI, vol. 19(2), pages 1-19, January.
Handle:
RePEc:gam:jijerp:v:19:y:2022:i:2:p:681-:d:720050
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:2:p:681-:d:720050. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.